-Reuters Citing IFAX
Related Posts
Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer
Actelis Receives New Orders To Supply 3 Military Bases With Cyber-Hardened Networking Technology, Continuing Its Momentum With The U.S. Military; No Financial Terms Disclosed
Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT applications, today announced that it has received new orders for
